Mabylon

Mabylon AG is a Swiss biotechnology company that utilizes naturally occurring human antibodies to treat allergies and neurodegenerative diseases. The company arose from research conducted by Professor Adriano Aguzzi and his colleagues at the University of Zurich (UZH) and the University Hospital Zurich (USZ). Compared to antibodies derived from animal models or artificial libraries, human-derived antibodies have better therapeutic potential. Moreover, they offer a unique opportunity to understand human biology and safety profiles of targets. However, human antibodies reacting to self-targets are under strict control and extremely rare in the general population. To identify these extremely rare human antibodies, Mabylon screens up to 100,000 human serum samples annually for the presence of target-specific antibodies. Using advanced B-cell screening technology, Mabylon can identify, clone, and express fully human antibodies, then test their preclinical therapeutic efficacy and clinical development potential.